Lipid trait variants and the risk of non-hodgkin lymphoma subtypes: a mendelian randomization study

Grants

Funding Acknowledgements

G. Kleinstern was supported by the NIHgrant R25 CA92049 (Mayo Cancer Genetic Epidemiology Training Program). Research reported in this article was supported by the NCI of the NIH under award number R01 CA200703 (to J.R. Cerhan). ATBC: Intramural Research Program of the NIH, NCI, Division of Cancer Epidemiology and Genetics.r CPSII: The American Cancer Society funds the creation, maintenance, and updating of the CPSII cohort. The authors thank the CPSII participants and Study Management Group for their invaluable contributions to this research. The authors would also like to acknowledge the contribution to this study from central cancer registries supported through the Centers for Disease Control and Prevention National Program of Cancer Registries, and cancer registries supported by the NCI Surveillance, Epidemiology, and End Results Program.r EPIC: Coordinated Action (Contract #006438, SP23-CT-2005-006438). HuGeF (Human Genetics Foundation), Torino, Italy.r EPILYMPH: European Commission (grant references QLK4-CT-2000-00422 and FOOD-CT-2006-023103); the Spanish Ministry of Health (grant references CIBERESP, PI11/01810, RCESP C03/09, RTICESP C03/10, and RTIC RD06/0020/0095), the Marato de TV3 Foundation (grant reference 051210), the Ag~encia de Gestiod'AjutsUniversitarisi de Recerca - Generalitat de Catalunya (grant reference 2009SGR1465), which had no role in the data collection, analysis, or interpretation of the results; the NIH (contract NO1-CO-12400); the Compagnia di San PaoloProgramma Oncologia; the Federal Office for Radiation Protection grants StSch4261 and StSch4420; the Jose Carreras Leukemia Foundation grant DJCLS-R12/23; the German Federal Ministry for Education and Research (BMBF-01-EO-1303); the Health Research Board, Ireland and Cancer Research Ireland; Czech Republic supported by MH CZ -DRO (MMCI, 00209805) and RECAMO, CZ.1.05/2.1.00/03.0101; and Fondation de France and Association de Recherche Contre le Cancer.r Spanish Ministry of Economy and Competitiveness - Carlos III Institute of Health cofunded by FEDER funds/European Regional Development Fund (ERDF) - a way to build Europe (grant numbers PI17/01280 and PI14/01219); Centro de Investigacion Biomedica en Red: Epidemiologia y Salud Publica [CIBERESP, Spain; grant sponsor: Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), CERCA Programme/Generalitat de Catalunya for institutional support; grant number: 2017SGR1085]. GEC: NIH CA 118444.r HPFS: The HPFS was supported in part by NIH grants UM1 CA167552, R01 CA149445, and R01 CA098122. We would like to thank the participants and staff of the Health Professionals Follow-Up Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, andWY. The study protocol was approved by the institutional review boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required.r Iowa-Mayo SPORE: NIH (CA97274), NCI Specialized Programs of Research Excellence (SPORE) in Human Cancer (P50 CA97274), Molecular Epidemiology of NonHodgkin Lymphoma Survival (R01 CA129539), and Henry J. Predolin Foundation.r Italian GxE: Italian Ministry for Education, University and Research (PRIN 2007 prot. 2007WEJLZB, PRIN 2009 prot. 20092ZELR2), and the Italian Association for Cancer Research (AIRC, Investigator Grant 11855).r Mayo Clinic Case-Control: NIH (R01 CA92153) and National Center for Advancing Translational Science (UL1 TR000135)r MCCS: The Melbourne Collaborative Cohort Study recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was further supported by Australian National Health and Medical Research Council (NHMRC) grants 209057, 251553, and 504711 and by infrastructure provided by Cancer Council Victoria.r MSKCC: Geoffrey Beene Cancer Research Grant, Lymphoma Foundation (LF5541). Barbara K. Lipman Lymphoma Research Fund (74419). Robert and Kate Niehaus Clinical Cancer Genetics Research Initiative (57470), U01 HG007033. ENCODE, U01 HG007033.r NCI-SEER: Intramural Research Program of the NCI, NIH, and Public Health Service (N01-PC-65064, N01-PC-67008, N01-PC-67009, N01-PC-67010, and N02-PC-71105).r NHS: TheNHS was supported in part by NIHgrantsUM1CA186107, PO1 CA87969, R01 CA49449, R01 CA149445, R01 CA098122, and R01 CA134958. We would like to thank the participants and staff of the Nurses' Health Study for their valuable contributions as well as the following state cancer registries for their help: AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE, NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY. The study protocol was approved by the institutional review boards of the Brigham and Women's Hospital and Harvard T.H. Chan School of Public Health, and those of participating registries as required.r NSW: Was supported by grants from the Australian National Health and Medical Research Council (ID990920), the Cancer Council NSW, and the University of Sydney Faculty of Medicine.r NYUWHS: NCI (UM1CA182934 and P30 CA016087) and National Institute of Environmental Health Sciences (ES000260).r PLCO: This research was supported by the Intramural Research Program of the NCI and by contracts from the Division of Cancer Prevention, NCI, NIH, DHHS.r SCALE: Swedish Cancer Society (2009/659), Stockholm County Council (20110209) and the Strategic Research Program in Epidemiology at Karolinska Institute, Swedish Cancer Society grant (02 6661), Danish Cancer Research Foundation Grant, Lundbeck Foundation Grant (R19-A2364), Danish Cancer Society Grant (DP 08-155), NIH (5R01 CA69669-02), and Plan Denmark.r UCSF: The UCSF studies were supported by the NCI, NIH, CA1046282 and CA154643. The collection of cancer incidence data used in this study was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; the NCI's Surveillance, Epidemiology, and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute; and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement #1U58 DP000807-01 awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the authors, and endorsement by the State of California, the California Department of Health Services, the NCI, or the Centers for Disease Control and Prevention or their contractors and subcontractors is not intended nor should be inferred.r UTAH: NIH CA134674, partial support for data collection at the Utah site was made possible by the Utah Population Database (UPDB) and the Utah Cancer Registry (UCR), partial support for all datasets within the UPDB is provided by the Huntsman Cancer Institute (HCI) and the HCI Comprehensive Cancer Center Support grant, P30 CA42014, and the UCR is supported in part by NIH contract HHSN261201000026C from the NCI SEER Program with additional support from the Utah State Department of Health and the University of Utah.r WHI: The WHI program is funded by the National Heart, Lung, and Blood Institute, NIH, U.S. Department of Health and Human Services through contracts HHSN268201600018C, HHSN268201600001C, HHSN268201600002C, HHSN268201600003C, and HHSN268201600004C. The authors thank the WHI investigators and staff for their dedication, and the study participants for making the program possible. A full listing of WHI investigators can be found at: http://www.whi.org/researchers/Documents%20%20Write%20a%20Paper/WHI% 20Investigator%20Long%20List.pdfr YALE: NCI (CA62006).